BR112023022041A2 - Anticorpos anti-tslp modificados - Google Patents

Anticorpos anti-tslp modificados

Info

Publication number
BR112023022041A2
BR112023022041A2 BR112023022041A BR112023022041A BR112023022041A2 BR 112023022041 A2 BR112023022041 A2 BR 112023022041A2 BR 112023022041 A BR112023022041 A BR 112023022041A BR 112023022041 A BR112023022041 A BR 112023022041A BR 112023022041 A2 BR112023022041 A2 BR 112023022041A2
Authority
BR
Brazil
Prior art keywords
modified anti
tslp antibodies
tslp
tezepelumab
antibodies
Prior art date
Application number
BR112023022041A
Other languages
English (en)
Portuguese (pt)
Inventor
Hao Zhang
Liuqing Shi
Pavel Bondarenko
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BR112023022041A2 publication Critical patent/BR112023022041A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112023022041A 2021-04-23 2022-04-22 Anticorpos anti-tslp modificados BR112023022041A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163178915P 2021-04-23 2021-04-23
PCT/US2022/025999 WO2022226342A2 (en) 2021-04-23 2022-04-22 Modified anti-tslp antibodies

Publications (1)

Publication Number Publication Date
BR112023022041A2 true BR112023022041A2 (pt) 2023-12-26

Family

ID=81597885

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022041A BR112023022041A2 (pt) 2021-04-23 2022-04-22 Anticorpos anti-tslp modificados

Country Status (14)

Country Link
US (1) US20240182558A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326762A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024516595A (cg-RX-API-DMAC7.html)
KR (1) KR20230175245A (cg-RX-API-DMAC7.html)
CN (1) CN117177992A (cg-RX-API-DMAC7.html)
AR (1) AR125404A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022262006A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022041A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216700A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003124A1 (cg-RX-API-DMAC7.html)
IL (1) IL307439A (cg-RX-API-DMAC7.html)
MX (1) MX2023012325A (cg-RX-API-DMAC7.html)
TW (1) TW202304980A (cg-RX-API-DMAC7.html)
WO (1) WO2022226342A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2024118542A1 (en) * 2022-11-28 2024-06-06 Takeda Vaccines, Inc. A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions
WO2024146630A1 (zh) * 2023-01-06 2024-07-11 江苏恒瑞医药股份有限公司 一种tslp抗体治疗哮喘的方法
TW202448501A (zh) 2023-02-02 2024-12-16 美商麥迪紐有限責任公司 用抗tslp抗體治療慢性鼻竇炎
WO2024238877A1 (en) 2023-05-18 2024-11-21 Medimmune, Llc Treatment of corticosteroid dependent asthma with anti-tslp antibody
IL330343A (en) 2024-01-05 2026-08-01 Medimmune Llc Treatment of chronic obstructive pulmonary disease using an anti-TSLP antibody
WO2025221247A1 (en) 2024-04-17 2025-10-23 Amgen Inc. Treatment of eosinophilic esophagitis with anti-tslp antibody
WO2025265071A1 (en) * 2024-06-21 2025-12-26 Paragon Therapeutics, Inc. Antibodies that bind tslp and methods of use
WO2026086808A1 (zh) * 2024-10-22 2026-04-30 海南先声药业有限公司 抗tslp抗体及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
EP1847602B1 (en) * 2005-01-12 2014-04-23 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG2 ANTIBODIES
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
EP3127921A1 (en) * 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
AT510032B1 (de) 2010-11-30 2012-01-15 Steiner Erwin Ing Montageeinrichtung für fassadenelemente
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
CN107428828A (zh) * 2015-03-11 2017-12-01 葛兰素史密斯克莱知识产权发展有限公司 Tslp结合蛋白
EP3609917A1 (en) * 2017-04-12 2020-02-19 Amgen Inc. Treatment of asthma with anti-tslp antibody
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
EA202090399A1 (ru) * 2017-08-01 2020-05-20 Эмджен Инк. Системы и способы для подготовки в режиме реального времени образца полипептида для анализа с помощью масс-спектрометрии
IL319987A (en) 2017-11-10 2025-06-01 Amgen Inc Plungers for drug delivery devices
WO2019178151A1 (en) 2018-03-13 2019-09-19 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
MA53913A (fr) 2018-10-15 2022-01-19 Amgen Inc Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament
JP7719714B2 (ja) 2018-10-15 2025-08-06 アムジエン・インコーポレーテツド ダンピング機構を有する薬物送達装置
EP4517327A3 (en) 2019-06-05 2025-05-07 Amgen Inc. Methods of identifying attributes of therapeutic proteins
JP7331298B2 (ja) * 2019-09-04 2023-08-23 ビオシオン インコーポレイテッド 抗体結合tslp及びその使用

Also Published As

Publication number Publication date
US20240182558A1 (en) 2024-06-06
WO2022226342A3 (en) 2022-12-01
AR125404A1 (es) 2023-07-12
EP4326762A2 (en) 2024-02-28
AU2022262006A1 (en) 2023-10-19
CA3216700A1 (en) 2022-10-27
JP2024516595A (ja) 2024-04-16
IL307439A (en) 2023-12-01
WO2022226342A2 (en) 2022-10-27
CN117177992A (zh) 2023-12-05
TW202304980A (zh) 2023-02-01
CL2023003124A1 (es) 2024-04-26
KR20230175245A (ko) 2023-12-29
MX2023012325A (es) 2023-10-30

Similar Documents

Publication Publication Date Title
MX2023012325A (es) Anticuerpos anti-tslp modificados.
WO2022031884A3 (en) Il2rg binding molecules and methods of use
WO2022032006A3 (en) Il2rb binding molecules and methods of use
WO2022040088A3 (en) Cd45 binding molecules and methods of use
EP4248996A3 (en) Anti-trem2 antibodies and methods of use thereof
BR112022018949A2 (pt) Anticorpos monoclonais humanos para síndrome respiratória aguda grave coronavírus 2 (sars-cov-2)
EA201991769A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С НИЗКИМ ПОКАЗАТЕЛЕМ pH, СОДЕРЖАЩАЯ КОНСТРУКЦИИ НА ОСНОВЕ АНТИТЕЛА, ОСУЩЕСТВЛЯЮЩИЕ РЕКРУТИНГ Т-КЛЕТОК
DE69227456D1 (de) Nachweis von kollagenabbau -i(in vivo)
ATE476992T1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
NO20064239L (no) Anti-AB-antistoff
BRPI0811198B8 (pt) fosfatase alcalina direcionada a osso, kits e métodos de seu uso
MX358705B (es) Agentes de union de esclerostina.
BR112013003262A2 (pt) anticorpos melhorados da classe igg4.
SA523450918B1 (ar) أجسام مضادة للنكتين-4 واستخداماتها
MX2015012562A (es) Purificacion de conjugados anticuerpo-farmaco (cafs).
BR112023021867A2 (pt) Composições de anticorpo anti-tslp e seus usos
MX2022010621A (es) Anticuerpos anti-cd19 humano.
WO2022031885A3 (en) Il10ra binding molecules and methods of use
AU2021269176A8 (en) Single domain antibodies binding to SARS-CoV-2 spike protein
BR112022011570A2 (pt) Anticorpos anti-mertk e métodos de uso dos mesmos
WO2022031942A3 (en) Il12rb2 binding molecules and methods of use
MX2021011530A (es) Composicion farmaceutica que contiene anticuerpos contra il-5 y su uso.
JOP20220193A1 (ar) صياغات من الأجسام المضادة لـ tslp البشرية وطرق لاستخدامها
MX2023005896A (es) Variantes de anticuerpos bovinos.
WO2022032005A3 (en) Il10rb binding molecules and methods of use